Pharmacotherapeutic considerations in solid organ transplant patients with COVID-19

References

• World Health Organization Web. [cited 2020 Mar 20]. Availabe from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
   Google Scholar
• Timsit JF, Sonneville R, Kalil A, et al. Diagnostic and therapeutic approach in infectious disease in solid organ transplant recipients. Intensive Care Med. 2019;45:573–591.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.
   Web of Science ®Google Scholar
• Guillen E, Pineiro GJ, Revuelta I, et al. Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? Am J Transplant. 2020;20(7):1875–1878.
   PubMed Web of Science ®Google Scholar
• Bartiromo M, Borchi B, Bottà A, et al. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19). Transpl Infect Dis. 2020. DOI:10.1111/tid.13286
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034.
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant. 2020;20:1849–1858.
   Web of Science ®Google Scholar
• Akalin E, Azzi BR, Parides M, et al. COVID-19 and kidney transplantation. New Engl J Med. 2020;382:2475–2477.
   PubMed Web of Science ®Google Scholar
• Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20:1800–1808.
   Web of Science ®Google Scholar
• Hoek RA, Manintveld OC, Betjes MG, et al. COVID-19 in solid organ transplant recipients: a single center experience. Transplant Int. 2020. DOI:10.1111/tri.13662
   Google Scholar
• Johnson KM, Belfer JJ, Peterson GR, et al. Managing COVID-19 in renal transplant recipients: a review of recent literature and case supporting corticosteroid-sparing immunosuppression. Pharmacotherapy. 2020;40:517–524.
   PubMed Web of Science ®Google Scholar
• Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;9:149–150.
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19-preliminary report. New Engl J Med. 2020. DOI:10.1056/NEJMoa2007764
   Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799.
   Web of Science ®Google Scholar
• Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomized, phase 2 trial. Lancet. 2020;395:1695–1704.
   Web of Science ®Google Scholar
• Alhazzani W, Moller MT, Arabi YM, et al. Surviving sepsis campaign: guideline on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;46:854–887.
   Web of Science ®Google Scholar
• Gattinoni L, Copolla S, Cressoni M, et al. COVID-19 does not lead to a “typical” acute respiratory syndrome. Am J Respir Crit Care Med. 2020;201(10):1299–1300.
   PubMed Web of Science ®Google Scholar
• Lexicomp. 2020 June.
   Google Scholar
• Bowman LJ, Brueckner AJ, Doligalski CT. The role of mTOR inhibitors in the management of viral infections: a review of current literature. Transplantation. 2018;102(2S):S50–9.
   PubMedGoogle Scholar
• Moes DJ, Guchelaar HJ, de Fijter JW. Sirolimus and everolimus in kidney transplantation. Drug Discov Today. 2015;20(10):1243–1249.
   PubMed Web of Science ®Google Scholar
• Mo Y, Fisher D. A review of treatment modalities for Middle East respiratory syndrome. J Antimicrob Chemother. 2016;71(12):3340–3350.
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Ng P, Chapman JR, et al. Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. Transplantation. 2016;100(8):1723–1731.
   PubMed Web of Science ®Google Scholar
• Shen L, Niu J, Wang C, et al. High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses. J Virol. 2019;93(12):e00023–19.
   PubMed Web of Science ®Google Scholar
• Qin J, Wang H, Qin X, et al. Perioperative presentation of COVID-19 disease in a liver transplant recipient. Hepatology. 2020. DOI:10.1002/hep.31257
   Web of Science ®Google Scholar
• Zhong Z, Zhang Q, Xia H, et al. Clinical characteristics and immunosuppressants management of coronavirus disease 2019 in solid organ transplant recipients. Am J Transplant. 2020;20:1916–1921.
   PubMed Web of Science ®Google Scholar
• Liverpool COVID-19 drug interactions. [cited 2020 June 25]. Availabe from: http://www.covid19-druginteractions.org/
   Google Scholar
• Manitpisitkul W, Wilson NS, Lee S, et al. Drug interactions in solid organ transplant recipients. In: Weir MR, Lerma EV, editors. Kidney transplantation: practical guide to management. Springer; 2014.
   Google Scholar
• Zhu L, Xu X, Ma K, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. 2020;20:1859–1863.
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the Joint European League against rheumatism and european renal association–European dialysis and transplant association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020. 1–11.
   PubMedGoogle Scholar